source
- Rezdiffra Beats Wall Street Forecasts as MASH Market ExpandsRezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
- Inhibrx reports 44% response rate when paired with Keytruda in head-and-neck cancer Phase 2 trialInhibrx Biosciences said its experimental agent INBRX-106 boosted the activity of Merck's Keytruda in a Phase 2 study of a head-and-neck cancer. The combination achieved a 44% overall response rate…